AbbVie's (NYSE: ABBV) share price has been hit pretty hard this year by the COVID-19 pandemic. But its underlying business hasn't.
The big drugmaker announced its first-quarter results before the market opened on Friday. AbbVie easily beat Wall Street's revenue and earnings estimates, delivering strong year-over-year growth on its top and bottom lines. The company also maintained its full-year 2020 adjusted earnings outlook, projecting 8.1% year-over-year growth at the midpoint of its guidance range.
All of these items are significant. But here are the three most important things to know about AbbVie's Q1 update.